Proteomic characterization of plasma-derived clotting factor VIII–von Willebrand factor concentrates
✍ Scribed by James G. Clifton; Feilei Huang; Spomenka Kovac; Xinli Yang; Douglas C. Hixson; Djuro Josic
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 320 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0173-0835
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Proteomic methods were used to identify the levels of impurities in three commercial plasma‐derived clotting factor VIII‐von Willebrand factor (FVIII/VWF) concentrates. In all three concentrates, significant amounts of other plasma proteins were found. In Octanate and Haemoctin, two concentrates developed in the 1990s, the major impurities identified were inter‐α inhibitor proteins, fibrinogen and fibronectin. These two concentrates were also found to contain additional components such as clotting factor II (prothrombin) that are known activators of FVIII. In Wilate, a recently developed FVIII/VWF concentrate, the amount of these impurities was significantly reduced. Batch‐to‐batch variations and differences between three investigated products were detected using iTRAQ, an isotope labeling technique for comparative MS, demonstrating the potential value of this technique for quality control analysis. The importance of thorough proteomic investigations of therapeutic FVIII/VWF preparations from human plasma is also discussed.
📜 SIMILAR VOLUMES
## Abstract Limited data are available regarding optimal treatment with desmopressin (DDAVP) or intermediate‐purity FVIII concentrates rich in VWF (CFCs) in patients with von Willebrand disease (VWD) who undergo planned surgery. We undertook a retrospective review over 10 years (1988–1997) and iden